(Q46597375)

English

Oral ondansetron is highly active as rescue antiemetic treatment for moderately emetogenic chemotherapy: results of a randomized phase II study

scientific article published on 14 May 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18478278

Oral ondansetron is highly active as rescue antiemetic treatment for moderately emetogenic chemotherapy: results of a randomized phase II study (English)

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18478278

Diana Giannarelli

5

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18478278

Isabella Sperduti

8

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18478278

object named as

Emilio Bria

10

0 references

author name string

Alessandra Fabi

1

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18478278

Mariangela Ciccarese

2

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18478278

Giulio Metro

3

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18478278

Antonella Savarese

4

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18478278

Carmen M Nuzzo

6

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18478278

Michelangelo Russillo

7

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18478278

Ilaria Carbone

9

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18478278

Francesco Cognetti

11

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18478278

publication date

14 May 2008

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18478278

Supportive Care in Cancer

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18478278

16

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18478278

1375-1380

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18478278

12

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18478278

https://scigraph.springernature.com/pub.10.1007/s00520-008-0438-9

0 references

Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron

1 reference

https://pubmed.ncbi.nlm.nih.gov/18478278

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference

1 reference

https://pubmed.ncbi.nlm.nih.gov/18478278

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chemotherapy-induced nausea and vomiting: state of the art in 2006.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18478278

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology

1 reference

https://pubmed.ncbi.nlm.nih.gov/18478278

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Control of chemotherapy-induced emesis

1 reference

https://pubmed.ncbi.nlm.nih.gov/18478278

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18478278

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Delayed emesis following anticancer chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/18478278

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron

1 reference

https://pubmed.ncbi.nlm.nih.gov/18478278

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The efficacy of a combination of ondansetron, methylprednisolone and metopimazine in patients previously uncontrolled with a dual antiemetic treatment in cisplatin-based chemotherapy. The French Ondansetron Study Group.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18478278

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antiemesis clinical practice guidelines in oncology.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18478278

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III ran

1 reference

https://pubmed.ncbi.nlm.nih.gov/18478278

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18478278

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serotonin antagonists in the management of cisplatin-induced emesis

1 reference

https://pubmed.ncbi.nlm.nih.gov/18478278

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/18478278

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Consensus proposal for 5HT3 antagonists in the prevention of acute emesis related to highly emetogenic chemotherapy. Dose, schedule, and route of administration.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18478278

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ondansetron plus metopimazine compared with ondansetron alone in patients receiving moderately emetogenic chemotherapy.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18478278

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prevention of chemotherapy- and radiotherapy-induced emesis: results of Perugia Consensus Conference. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC)

1 reference

https://pubmed.ncbi.nlm.nih.gov/18478278

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00520-008-0438-9

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18478278

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18478278

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46597375&oldid=2121323765"